← Back to Screener
US Stock Screener
HomeScreensNewsWatchlist
...
HomeStocksRVMDRevenue History
OverviewPriceRevenueEarningsP/ERatiosDividendTargets

Revolution Medicines, Inc. (RVMD) Revenue History

Annual and quarterly revenue from 2017 to 2025

TTM Revenue
$0
0
YoY Growth
-
Latest Quarter
$0
Q4 2025
QoQ Growth
-

Compound Annual Growth Rate (CAGR)

3-Year-
5-Year-
10-Year-
Highest Annual Revenue$50.0M (2019)
Highest Quarter$15.3M (Q4 2022)

Loading revenue history...

Revenue Growth Metrics

1-Year Growth
-
3-Year CAGR
-
5-Year CAGR
-
10-Year CAGR
-
TTM vs Prior Year-
Peak Annual Revenue$50.0M (2019)

Revenue Breakdown (FY 2022)

RVMD's revenue distribution by segment and geography for fiscal year 2022

By Product/Segment

Collaboration Revenue Member100.0%

Download Historical Data

9 records • Includes OHLCV + Technical Indicators (MA50, MA200, RSI)

Free sign in required to download data

RVMD Revenue Analysis (2017–2025)

As of March 2, 2026, Revolution Medicines, Inc. (RVMD) generated trailing twelve-month (TTM) revenue of $0. The most recent quarter (Q4 2025) recorded $0 in revenue.

Looking at the longer-term picture, RVMD's historical revenue data shows various trends over time. The company achieved its highest annual revenue of $50.0 million in 2019.

Revenue diversification analysis shows RVMD's business is primarily driven by Collaboration Revenue Member (100%). With over half of revenue concentrated in Collaboration Revenue Member, the company maintains significant focus in this area while developing other growth vectors.

When compared to Healthcare sector peers including INCY (+21.2% YoY), GMAB (+21.0% YoY), and EXEL (+9.9% YoY). Compare RVMD vs INCY →

Peer Comparison

Compare RVMD's revenue metrics with industry peers

CompanyTTM RevenueYoY Growth5Y CAGROp. MarginCompare
RVMDCurrent$0---
INCY$5.1B+21.2%+14.0%26.1%
GMAB$21.5B+21.0%+32.0%31.1%
EXEL$2.3B+9.9%+18.6%37.6%
IBRX$15M+1026.0%+221.4%-2334.2%
MRUS$35M+55.9%+4.7%-753.0%
Best in groupLowest in group

Historical Revenue Data

Showing 9 of 9 records
Year Revenue YoY % Gross Profit Gross Margin Op. Income Op. Margin
2025$0-$-16,558,000-$-1,182,369,000-
2024$0-100.0%$0-$-689,524,000-
2023$11.6M-67.3%$11.6M100.0%$-487,185,000-4207.1%
2022$35.4M+20.4%$35.4M100.0%$-258,279,000-730.0%
2021$29.4M-31.6%$29.4M100.0%$-188,008,000-639.7%
2020$43.0M-14.1%$43.0M100.0%$-110,697,000-257.5%
2019$50.0M+148.2%$50.0M100.0%$-54,120,000-108.2%
2018$20.2M-$20.2M100.0%$-40,329,000-200.0%
2017$0-$-26,586,000-$-31,129,000-

See RVMD's True Return

Price is only half the story. See total return with reinvested dividends.

Launch Calculator

Is RVMD Undervalued?

See our Bear / Base / Bull DCF models and intrinsic value estimates.

View Valuation

Compare RVMD vs AGIO

See how RVMD stacks up against sector leader Agios Pharmaceuticals, Inc..

Start Comparison

Frequently Asked Questions

Is RVMD's revenue growth accelerating or slowing?

RVMD TTM revenue: $0.00. YoY growth: N/A. 5-year CAGR: N/A.

What is RVMD's long-term revenue growth rate?

Revolution Medicines, Inc.'s 5-year revenue CAGR of N/A reflects the variable expansion pattern. Current YoY growth of N/A is near this long-term average.

How is RVMD's revenue distributed by segment?

RVMD reports revenue by product line and geographic region. Annual and quarterly breakdowns from 2017-2025 are available for download. Segment mix reveals concentration and diversification trends.

VCP Scanner

Find stocks. Verify deeply. Act with conviction.

Patterns find ideas. Fundamentals build conviction.

Data updated daily

Quick Links

  • Home
  • Screens
  • Valuation
  • Compare
  • Total Return
  • News
  • Insights
  • Methodology
  • How It Works
  • Profile

Popular Screens

  • VCP Hot
  • VCP Warm
  • Value Screens
  • Growth Screens
  • Momentum Screens
  • Technical Screens
  • Quality Screens

Community

  • Twitter
  • Get Early Access
© 2026 VCP Scanner. All rights reserved.
Made with ❤️ for investors
Not financial advice. Do your own research.

Revenue Over Time